XORTX Therapeutics Inc
XRTX0.400USD
-0.002-0.40%
Fechamento 02/06, 16:00（ET）Cotações atrasadas em 15 min
2.09MValor de mercado
PerdaP/L TTM
Mais detalhes de XORTX Therapeutics Inc Empresa
XORTX Therapeutics Inc. is a pharmaceutical company. The Company is engaged in developing medications that improve the quality of life and health of individuals with gout and other important diseases. It has three clinically advanced products in development: its lead program, XRx-026 program for the treatment of gout; XRx-008 program for autosomal dominant polycystic kidney disease (ADPKD); and XRx-101 for acute kidney and other acute organ injury associated with respiratory virus infections. In addition, the Company is developing XRx-225, a pre-clinical stage program for Type II diabetic nephropathy. It is working to advance products that target aberrant purine metabolism and xanthine oxidase to decrease or inhibit the production of uric acid. The XRx-026 program is designed to decrease the chronically high serum uric acid concentration in the blood (SUA) by inhibiting the production of uric acid by the xanthine oxidase enzyme by administering a xanthine oxidase inhibitor-oxypurinol.
Informações de XORTX Therapeutics Inc
Código da empresaXRTX
Nome da EmpresaXORTX Therapeutics Inc
Data de listagemSep 30, 2015
CEODavidoff (Allen W)
Número de funcionários2
Tipo de títulosOrdinary Share
Fim do ano fiscalSep 30
Endereço3710 - 33rd Street NW
CidadeCALGARY
Bolsa de valoresNASDAQ OMX - NASDAQ BASIC
PaísCanada
Código postalT2L 2M1
Telefone14034557727
Sitehttps://www.xortx.com/
Código da empresaXRTX
Data de listagemSep 30, 2015
CEODavidoff (Allen W)
Executivos da empresa XORTX Therapeutics Inc
Nome
Nome/Posição
Posição
Ações detidas
Variação
Dr. Allen W. Davidoff, Ph.D.
Dr. Allen W. Davidoff, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Mr. Paul J. Van Damme
Mr. Paul J. Van Damme
Independent Director
Independent Director
--
--
Dr. Stephen Haworth
Dr. Stephen Haworth
Chief Medical Officer
Chief Medical Officer
--
--
Mr. William (Bill) Farley
Mr. William (Bill) Farley
Independent Director
Independent Director
--
--
Dr. Raymond Dennis (Ray) Pratt, M.D.
Dr. Raymond Dennis (Ray) Pratt, M.D.
Independent Director
Independent Director
--
--
Mr. Anthony J. Giovinazzo
Mr. Anthony J. Giovinazzo
Independent Non-Executive Chairman of the Board
Independent Non-Executive Chairman of the Board
--
--
Mr. Stacy Evans, M.D.
Mr. Stacy Evans, M.D.
Chief Business Officer
Chief Business Officer
--
--
Mr. Patrick Treanor
Mr. Patrick Treanor
Independent Director
Independent Director
--
--
Ms. Abigail Jenkins
Ms. Abigail Jenkins
Independent Director
Independent Director
--
--
Mr. Michael Bumby
Mr. Michael Bumby
Chief Financial Officer
Chief Financial Officer
--
--
Nome
Nome/Posição
Posição
Ações detidas
Variação
Dr. Allen W. Davidoff, Ph.D.
Dr. Allen W. Davidoff, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Mr. Paul J. Van Damme
Mr. Paul J. Van Damme
Independent Director
Independent Director
--
--
Dr. Stephen Haworth
Dr. Stephen Haworth
Chief Medical Officer
Chief Medical Officer
--
--
Mr. William (Bill) Farley
Mr. William (Bill) Farley
Independent Director
Independent Director
--
--
Dr. Raymond Dennis (Ray) Pratt, M.D.
Dr. Raymond Dennis (Ray) Pratt, M.D.
Independent Director
Independent Director
--
--
Mr. Anthony J. Giovinazzo
Mr. Anthony J. Giovinazzo
Independent Non-Executive Chairman of the Board
Independent Non-Executive Chairman of the Board
--
--
Detalhamento da receita
Os dados relevantes ainda não foram divulgados pela empresa.
Os dados relevantes ainda não foram divulgados pela empresa.
Por Empresa
Por Região
Os dados relevantes ainda não foram divulgados pela empresa.
Distribuição de ações
Atualizado em: sex, 6 de fev
Atualizado em: sex, 6 de fev
Investidores
Tipos de investidores
Investidores
Investidores
Proporção
Lincoln Alternative Strategies LLC
8.22%
Davidoff, Allen Warren
1.73%
Citadel Advisors LLC
1.24%
Baader Bank AG
0.27%
XTX Markets LLC
0.20%
Outro
88.34%
Investidores
Investidores
Proporção
Lincoln Alternative Strategies LLC
8.22%
Davidoff, Allen Warren
1.73%
Citadel Advisors LLC
1.24%
Baader Bank AG
0.27%
XTX Markets LLC
0.20%
Outro
88.34%
Tipos de investidores
Investidores
Proporção
Corporation
8.22%
Individual Investor
1.91%
Hedge Fund
1.24%
Investment Advisor/Hedge Fund
0.27%
Venture Capital
0.20%
Investment Advisor
0.03%
Outro
88.13%
Participação acionária institucional
Atualizado em: qua, 21 de jan
Atualizado em: qua, 21 de jan
Período do relatório
N.º de instituições
Ações detidas
Proporção
Variação
2026Q4
10
101.02K
4.75%
--
2025Q4
16
102.18K
1.47%
-649.58K
2025Q3
16
63.97K
1.23%
-645.66K
2025Q2
17
129.44K
3.30%
-739.58K
2025Q1
20
127.29K
3.49%
-606.22K
2024Q4
21
385.20K
10.34%
-244.07K
2024Q3
22
287.39K
12.35%
-145.77K
2024Q2
20
276.67K
12.12%
-141.93K
2024Q1
21
272.84K
13.24%
-121.02K
2023Q4
19
553.49K
27.69%
+481.09K
Ver Mais
Atividade dos acionistas
Nome
Ações detidas
Proporção
Variação
Var. %
Data
Lincoln Alternative Strategies LLC
572.47K
8.22%
+572.47K
--
Oct 23, 2025
Davidoff, Allen Warren
120.45K
1.73%
+8.19K
+7.30%
Jul 22, 2025
Citadel Advisors LLC
86.33K
1.24%
+47.86K
+124.41%
Sep 30, 2025
XTX Markets LLC
13.82K
0.2%
+13.82K
--
Sep 30, 2025
Giovinazzo (Anthony)
9.63K
0.14%
--
--
Apr 30, 2025
UBS Financial Services, Inc.
234.00
0%
-20.56K
-98.87%
Sep 30, 2025
RBC Dominion Securities, Inc.
358.00
0.01%
-305.00
-46.00%
Sep 30, 2025
Van Damme (Paul Joseph)
324.00
0%
-6.79K
-95.44%
Oct 17, 2025
Ver Mais
ETFs Relacionados
Nome
Proporção
Sem dados
Dividendo
Um total de
0.00
USD foi distribuído em dividendos nos últimos 5 anos.
Data
Dividendo
Data de registro
Data de pagamento
Data ex-dividendo
Sem dados
Desdobramento de ações
Data
Data ex-dividendo
Tipo
Proporção
Oct 12, 2023
Merger
9→1
Oct 12, 2023
Merger
9→1
Oct 12, 2023
Merger
9→1
Oct 12, 2023
Merger
9→1
Data
Data ex-dividendo
Tipo
Proporção
Oct 12, 2023
Merger
9→1
Oct 12, 2023
Merger
9→1
Oct 12, 2023
Merger
9→1
Oct 12, 2023
Merger
9→1
